CFRX ContraFect Corporation gains 16% Oct 11, 2017

ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York. http://www.priceseries.com/trade/CFRX-ContraFect-Corporation-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2017092720171011.html